Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, HC Wainwright Analyst Says

Roivant Sciences (NASDAQ:ROIV) had its target price raised by equities research analysts at HC Wainwright from $33.00 to $34.00 in a research note issued to investors on Wednesday, Marketbeat reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 14.40% from the stock’s current price.

A number of other equities analysts also recently weighed in on ROIV. The Goldman Sachs Group boosted their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Guggenheim lifted their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Citigroup boosted their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $28.81.

Roivant Sciences Stock Up 0.7%

ROIV stock opened at $29.72 on Wednesday. The company has a market cap of $21.27 billion, a price-to-earnings ratio of -25.40 and a beta of 1.17. Roivant Sciences has a twelve month low of $8.73 and a twelve month high of $30.03. The business has a 50 day moving average price of $24.43 and a two-hundred day moving average price of $19.92.

Insiders Place Their Bets

In other news, Director Daniel Allen Gold sold 917,282 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28. Following the transaction, the director owned 17,130,445 shares of the company’s stock, valued at approximately $394,685,452.80. This represents a 5.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total value of $43,389,841.68. Following the transaction, the insider owned 36,350,621 shares in the company, valued at approximately $798,259,637.16. This trade represents a 5.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,318,014 shares of company stock worth $315,727,023 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in ROIV. Penn Davis Mcfarland Inc. raised its stake in Roivant Sciences by 10.1% in the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after purchasing an additional 170,456 shares in the last quarter. Valeo Financial Advisors LLC acquired a new position in shares of Roivant Sciences during the 2nd quarter worth approximately $1,145,000. TD Asset Management Inc increased its holdings in shares of Roivant Sciences by 94.7% during the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock worth $4,784,000 after purchasing an additional 153,800 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Roivant Sciences by 25.4% during the third quarter. New York State Common Retirement Fund now owns 229,037 shares of the company’s stock worth $3,465,000 after purchasing an additional 46,344 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $997,000. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.